Xortx Therapeutics Stock Cash Per Share

XRTX Stock

USD 1.21 0.03 2.54%

XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.

		Last Reported	Projected for Next Year
	Cash Per Share	2.29	2.14

Cash Per Share is likely to drop to 2.14 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

XORTX Therapeutics Company Cash Per Share Analysis

XORTX Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cash Per Share

Total Cash

Average Shares

More About Cash Per Share | All Equity Analysis

Current XORTX Therapeutics Cash Per Share

1.03 X

Most of XORTX Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XORTX Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

XORTX Cash Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for XORTX Therapeutics is extremely important. It helps to project a fair market value of XORTX Stock properly, considering its historical fundamentals such as Cash Per Share. Since XORTX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XORTX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XORTX Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Net Tangible Assets	Long Term Debt	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue
Total Assets		0.98	-0.99	-0.58	0.53	0.76	0.89	1.0	-0.43	-0.74	0.91	0.56	-0.15	0.97	-0.62	1.0	0.84	0.73	0.92	-0.15
Total Stockholder Equity	0.98		-0.98	-0.55	0.39	0.71	0.8	0.98	-0.45	-0.75	0.92	0.56	-0.17	0.99	-0.58	0.99	0.83	0.73	0.93	-0.17
Net Debt	-0.99	-0.98		0.51	-0.51	-0.73	-0.88	-0.99	0.38	0.7	-0.89	-0.48	0.12	-0.97	0.54	-0.99	-0.79	-0.67	-0.89	0.12
Retained Earnings	-0.58	-0.55	0.51		-0.49	-0.82	-0.49	-0.55	0.77	0.86	-0.78	-0.9	0.71	-0.53	0.85	-0.59	-0.89	-0.88	-0.77	0.71
Accounts Payable	0.53	0.39	-0.51	-0.49		0.67	0.83	0.52	-0.23	-0.3	0.33	0.44	0.11	0.34	-0.56	0.49	0.53	0.35	0.37	0.11
Net Receivables	0.76	0.71	-0.73	-0.82	0.67		0.74	0.74	-0.65	-0.78	0.78	0.77	-0.35	0.65	-0.72	0.75	0.9	0.75	0.81	-0.35
Total Liab	0.89	0.8	-0.88	-0.49	0.83	0.74		0.89	-0.27	-0.54	0.68	0.46	0.08	0.78	-0.57	0.86	0.71	0.56	0.71	0.08
Total Current Assets	1.0	0.98	-0.99	-0.55	0.52	0.74	0.89		-0.42	-0.71	0.89	0.54	-0.13	0.97	-0.61	1.0	0.82	0.71	0.9	-0.13
Short Term Debt	-0.43	-0.45	0.38	0.77	-0.23	-0.65	-0.27	-0.42		0.58	-0.61	-0.84	0.56	-0.43	0.83	-0.46	-0.73	-0.67	-0.58	0.56
Intangible Assets	-0.74	-0.75	0.7	0.86	-0.3	-0.78	-0.54	-0.71	0.58		-0.91	-0.71	0.65	-0.73	0.62	-0.75	-0.89	-0.95	-0.92	0.65
Net Tangible Assets	0.91	0.92	-0.89	-0.78	0.33	0.78	0.68	0.89	-0.61	-0.91		0.7	-0.53	0.92	-0.68	0.93	0.91	0.87	0.98	-0.53
Long Term Debt	0.56	0.56	-0.48	-0.9	0.44	0.77	0.46	0.54	-0.84	-0.71	0.7		-0.48	0.54	-0.94	0.57	0.9	0.78	0.72	-0.48
Deferred Long Term Liab	-0.15	-0.17	0.12	0.71	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48		-0.21	0.41	-0.2	-0.44	-0.61	-0.44	1.0
Net Invested Capital	0.97	0.99	-0.97	-0.53	0.34	0.65	0.78	0.97	-0.43	-0.73	0.92	0.54	-0.21		-0.58	0.98	0.81	0.71	0.92	-0.21
Short Long Term Debt	-0.62	-0.58	0.54	0.85	-0.56	-0.72	-0.57	-0.61	0.83	0.62	-0.68	-0.94	0.41	-0.58		-0.63	-0.86	-0.76	-0.67	0.41
Net Working Capital	1.0	0.99	-0.99	-0.59	0.49	0.75	0.86	1.0	-0.46	-0.75	0.93	0.57	-0.2	0.98	-0.63		0.85	0.75	0.93	-0.2
Common Stock	0.84	0.83	-0.79	-0.89	0.53	0.9	0.71	0.82	-0.73	-0.89	0.91	0.9	-0.44	0.81	-0.86	0.85		0.9	0.94	-0.44
Property Plant Equipment	0.73	0.73	-0.67	-0.88	0.35	0.75	0.56	0.71	-0.67	-0.95	0.87	0.78	-0.61	0.71	-0.76	0.75	0.9		0.88	-0.61
Capital Stock	0.92	0.93	-0.89	-0.77	0.37	0.81	0.71	0.9	-0.58	-0.92	0.98	0.72	-0.44	0.92	-0.67	0.93	0.94	0.88		-0.44
Current Deferred Revenue	-0.15	-0.17	0.12	0.71	0.11	-0.35	0.08	-0.13	0.56	0.65	-0.53	-0.48	1.0	-0.21	0.41	-0.2	-0.44	-0.61	-0.44

Click cells to compare fundamentals

XORTX Cash Per Share Historical Pattern

Today, most investors in XORTX Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various XORTX Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of XORTX Therapeutics cash per share as a starting point in their analysis.

XORTX Therapeutics Cash Per Share

Timeline

Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Competition

Predict XORTX Therapeutics

Cash Per Share Over Time

XORTX Common Stock Shares Outstanding

Common Stock Shares Outstanding

2.08 Million

At this time, XORTX Therapeutics' Common Stock Shares Outstanding is fairly stable compared to the past year.

In accordance with the recently published financial statements, XORTX Therapeutics has a Cash Per Share of 1.03 times. This is 76.32% lower than that of the Biotechnology sector and 76.21% lower than that of the Health Care industry. The cash per share for all United States stocks is 79.44% higher than that of the company.

XORTX Cash Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XORTX Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XORTX Therapeutics could also be used in its relative valuation, which is a method of valuing XORTX Therapeutics by comparing valuation metrics of similar companies.

XORTX Therapeutics is currently under evaluation in cash per share category among its peers.

XORTX Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of XORTX Therapeutics from analyzing XORTX Therapeutics' financial statements. These drivers represent accounts that assess XORTX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XORTX Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	8.0M	10.1M	11.3M	134.3M	5.7M	5.5M
Enterprise Value	7.8M	10.1M	11.2M	123.9M	2.3M	2.2M

XORTX Fundamentals

	Return On Equity	-0.29
	Return On Asset	-0.33
	Current Valuation	1.78 M
	Shares Outstanding	3.22 M
	Shares Owned By Insiders	3.01 %
	Shares Owned By Institutions	6.03 %
	Number Of Shares Shorted	3.74 K
	Price To Earning	170.67 X
	Price To Book	1.83 X
	EBITDA	(6.47 M)
	Net Income	(2.16 M)
	Cash And Equivalents	13.42 M
	Cash Per Share	1.03 X
	Total Debt	11.51 K
	Debt To Equity	0.01 %
	Current Ratio	14.09 X
	Book Value Per Share	2.32 X
	Cash Flow From Operations	(6.58 M)
	Short Ratio	0.02 X
	Earnings Per Share	0.12 X
	Price To Earnings To Growth	9.08 X
	Target Price	12.17
	Beta	-0.21
	Market Capitalization	4.34 M
	Total Asset	5.47 M
	Retained Earnings	(17.85 M)
	Working Capital	3.77 M
	Current Asset	341.74 M
	Current Liabilities	109.37 M
	Net Asset	5.47 M

About XORTX Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC